Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LXRX stock, giving a Buy rating yesterday.Invest with Confidence: ...

Our goal is to provide novel therapeutic modalities that would not only alleviate neuropathic pain in patients with diabetes but, even more importantly, also halt its progression without causing ...

The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive. The Food and Drug ...

Transcutaneous electrical nerve stimulation (TENS) may help provide pain relief for people with diabetic neuropathy. However, more research is necessary. Some research suggests that high and low ...

THE WOODLANDS, Texas, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the company will host a virtual webcast: “LX9211 - Changing the Paradigm for ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

the event will offer an in-depth overview on LX9211 for the treatment of diabetic peripheral neuropathic pain (DPNP), featuring remarks from Lexicon leaders including: In addition to presentations ...

The FDA has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.